Cover Image
市場調查報告書

全球反義、RNAi治療藥市場未來趨勢

Global Antisense and RNAi Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318835
出版日期 內容資訊 英文 70 Pages
訂單完成後即時交付
價格
Back to Top
全球反義、RNAi治療藥市場未來趨勢 Global Antisense and RNAi Therapeutics Market 2015-2019
出版日期: 2014年11月12日 內容資訊: 英文 70 Pages
簡介

反義及RNAi治療,是用於生命垂危的慢性疾病及罕見疾病的治療方法,新的劃時代的治療選項。所謂RNAi是透過RNA分子清楚破壞mRNA分子以阻礙基因表現,以RNA為基礎的基因表現抑制流程。反義技術中,包含與mRNA和mRNA前驅體的剪接部位結合,有效鈍化其活動之核酸鏈的合成。RNAi及反義,是為了研究、診斷及治療各種用途,製藥企業和研究機關及其他所使用的主要技術。RNAi治療藥,適用於癌症和神經退化性疾病等各種疾病的治療。RNAi技術所使用的RNA分子,有miRNA及siRNA的2種。全球反義、RNAi治療藥市場2013∼2018年的年複合成長率(CAGR)預計達到10.86%。

本報告提供全球的反義及RNAi(RNA干擾)的治療藥市場相關分析、市場概要和結構、市場規模趨勢(今後5年的預測值)、各技術、治療領域、地區的詳細趨勢、推動及阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各技術的市場區隔

第8章 各治療領域的市場區隔

第9章 地理區隔

  • 南北美洲的反義、RNAi治療藥市場
  • 歐洲、中東、非洲(EMEA)地區的反義、RNAi治療藥市場
  • 亞太地區的反義、RNAi治療藥市場

第10章 購買標準

第11章 開發中產品現況

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • 企業合併、收購(M&A)及共同開發
  • 供應商分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Alnylam Pharmaceuticals
    • 主要資料
    • 產業概要
    • 財務實際成果
    • 最近的發展趨勢
    • SWOT分析
  • Isis Pharmaceuticals
  • Sanofi SA
  • Tekmira Pharmaceuticals

第20章 相關報告

圖表一覽

目錄
Product Code: IRTNTR4600

About Antisense and RNAi Therapeutics

Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to an mRNA or to a splicing site on pre-mRNA and inactivates it effectively. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA.

TechNavio's analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Antisense and RNAi Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of antisense and RNAi therapeutics used for the treatment of various serious chronic diseases including:

  • Infectious diseases
  • Cardiovascular diseases
  • Kidney diseases
  • Cancer
  • Metabolic disorders
  • Others

The report also covers the two main technologies, i.e., Antisense and RNAi technology, which are used by vendors to develop antisense and RNAi therapeutics.

TechNavio's report, the Global Antisense and RNAi Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Antisense and RNAi Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Alnylam Pharmaceuticals
  • Isis Pharmaceuticals
  • Sanofi
  • Tekmira Pharmaceuticals

Other Prominent Vendors

  • Acuitas Therapeutics
  • Allergan
  • Antisense Therapeutics
  • Ascletis
  • AstraZeneca
  • Atlantic Pharmaceuticals
  • Benitec Biopharma
  • Biogen Idec
  • Bristol-Myers Squibb
  • Dainippon Sumitomo Pharma
  • Dicerna Pharmaceuticals
  • Enzon Pharmaceuticals
  • F. Hoffmann-La Roche
  • Glaxosmithkline
  • Gradalis
  • iCo Therapeutics
  • Kyowa Hakko Kirin
  • Marina Biotech
  • Novartis
  • OncoGenex Pharmaceuticals
  • OPKO Health
  • Pfizer
  • Quark Pharmaceuticals
  • Regulus Therapeutics
  • Silence Therapeutics
  • Spectrum Pharmaceuticals
  • Sylentis
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • The Medicines Company
  • TransDerm

Market Driver

  • Advances in Technology
  • For a full, detailed list, view our report

Market Challenge

  • Toxicity of Antisense and RNAi Molecules-based Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increased Strategic Collaborations and Licensing Activities
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Technology

08. Market Segmentation by Therapeutics Area

09. Geographical Segmentation

  • 09.1. Antisense and RNAi Therapeutics Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Antisense and RNAi Therapeutics Market in EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. Antisense and RNAi Therapeutics Market in APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Pipeline Snapshot

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions and Collaborations
  • 18.2. Vendor Analysis 2014
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Alnylam Pharmaceuticals
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Financial Performance
    • 19.1.4. Recent Developments
    • 19.1.5. SWOT Analysis
  • 19.2. Isis Pharmaceuticals
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Revenue Comparison 2011 and 2013
    • 19.2.4. Recent Developments
    • 19.2.5. SWOT Analysis
  • 19.3. Sanofi SA
    • 19.3.1. Key Facts
    • 19.3.2. Business Description
    • 19.3.3. Business Segmentation
    • 19.3.4. Revenue by Business Segmentation
    • 19.3.5. Revenue Comparison 2012 and 2013
    • 19.3.6. Sales by Geography
    • 19.3.7. Business Strategy
    • 19.3.8. Key Developments
    • 19.3.9. SWOT Analysis
  • 19.4. Tekmira Pharmaceuticals
    • 19.4.1. Key Facts
    • 19.4.2. Business Overview
    • 19.4.3. Financial Performance
    • 19.4.4. Key Developments
    • 19.4.5. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Antisense and RNAi Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 3: Global Antisense and RNAi Therapeutics Market Segmentation by Technology
  • Exhibit 4: Global Antisense and RNAi Therapeutics Market Segmentation by Technology 2014
  • Exhibit 5: Global Antisense and RNAi Therapeutics Market by Therapeutics Area
  • Exhibit 6: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 7: Antisense and RNAi Therapeutics Market in Americas 2014-2019 (US$ million)
  • Exhibit 8: Antisense and RNAi Therapeutics Market in EMEA Region 2014-2019 (US$ million)
  • Exhibit 9: Antisense and RNAi Therapeutics Market in APAC Region 2014-2019 (US$ million)
  • Exhibit 10: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019 (US$ million)
  • Exhibit 11: Global Antisense and RNAi Therapeutics Market by Geographical Segmentation 2014-2019
  • Exhibit 12: Alnylam Pharmaceuticals: Financial Performance 2013-2012 (in million)
  • Exhibit 13: Isis Pharmaceuticals: Revenue Comparison 2011 and 2013(US$ million)
  • Exhibit 14: Sanofi SA: Business Segmentation
  • Exhibit 15: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 16: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 17: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
  • Exhibit 18: Tekmira Pharmaceuticals: Financial Performance 2012-2013
Back to Top